ビラスチン
Bilastine
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
基本情報
- CAS
202189-78-4- 標準SMILES
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21- InChIKey
ACCMWZWAEFYUGZ-UHFFFAOYSA-N- 分子式
- C28H37N3O3
- 平均分子量
- 463.6 g/mol
- 単同位体質量
- 463.28349204
概要
Bilastine is a member of benzimidazoles.
名称と識別子
- 優先名称
- Bilastine
- IUPAC
- 2-[4-[2-[4-[1-(2-ethoxyethyl)benzimidazol-2-yl]piperidin-1-yl]ethyl]phenyl]-2-methylpropanoic acid
- 現地名
- ビラスチン
- 英語名
- Bilastine
- 分子式
- C28H37N3O3
- 分子量
- 463.62
名称と別名
Bilastine202189-78-4Ilaxten2-[4-[2-[4-[1-(2-ethoxyethyl)benzimidazol-2-yl]piperidin-1-yl]ethyl]phenyl]-2-methylpropanoic acidBilastinaDTXSID5057678PA1123N395DTXCID6031467Bilastinump-(2-(4-(1-(2-Ethoxyethyl)-2-benzimidazolyl)piperidino)ethyl)-alpha-methylhydratropic acid2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-1,3-benzodiazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic acid2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-1,3-benzodiazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acid
名称をさらに表示
ビラスチンビラスチン (JAN)2-[4-[2-[4-[1-(2-エトキシエチル)-1H-ベンゾイミダゾール-2-イル]ピペリジン-1-イル]エチル]フェニル]-2-メチルプロパン酸2-[4-(2-{4-[1-(2-エトキシエチル)-1H-1,3-ベンゾジアゾール-2-イル]ピペリジン-1-イル}エチル)フェニル]-2-メチルプロパン酸ビラノアBilastin2-(4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZO[D ]IMIDAZOL-2-YL) PIPERIDIN-1-YL)ETHY)PHEN YL)-2-METHYLPROPANOIC ACIDBilatexBilastenBilestinBilasteneD6-Bilastine
2-(4-(2-(4-(1-(2-ethoxyethyl)benzimidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acidRefChem:568338R06AX292-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acidBilaxtenBilastine [INN]MFCD09837814GTPL11579
データベース識別子
- CAS
202189-78-4- PubChem CID
- 185460
- DTXSID
DTXSID5057678- ChEMBL
CHEMBL1742423- ChEBI
CHEBI:135954- UNII
- PA1123N395
- EC Number
- 824-988-5
- Nikkaji
- J3.277.525J
物性
構造計算による物性補完中
- XLogP
- 2.3
- 極性表面積
- 67.6 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 5
- 回転可能結合数
- 10
- 重原子数
- 34
- 形式電荷
- 0
- 複雑度
- 641
実験および物理化学的性質
Drugs
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Used in Switzerland
Human DrugsBreast Feeding; Lactation; Milk, Human; Antihistamines; Nonsedating Antihistamines; Histamine Antagonists
物理化学的性質
- 融点
- 202 °C · 202 °C
- 沸点
- 639.1 · 639.1±55.0 °C(Predicted)
- 比重(密度)
- 1.16 · 1.16±0.1 g/cm3(Predicted)
- 貯蔵温度
- Sealed in dry,Room Temperature
- 水溶解度
- Insoluble in water
- 溶解性
- 49.3 · DMSO:49.3(Max Conc. mg/mL);106.34(Max Conc. mM)
- 酸解離定数(Pka)
- 4.4 · 4.40±0.10(Predicted)
- 外見
- powder to crystal
- 色
- White to Light yellow
- InChI
- 1S/C28H37N3O3/c1-4-34-20-19-31-25-8-6-5-7-24(25)29-26(31)22-14-17-30(18-15-22)16-13-21-9-11-23(12-10-21)28(2,3)27(32)33/h5-12,22H,4,13-20H2,1-3H3,(H,32,33)
- InChIKey
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N
- SMILES
- C(N1C2=CC=CC=C2N=C1C1CCN(CCC2C=CC(C(C)(C)C(=O)O)=CC=2)CC1)COCC
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
危険有害性情報
Hazard Classes and CategoriesAcute Tox. 4 (100%)
毒性情報
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
安全データ
- wgk
- WGK 3
- hs_code
- 2933.39.4100
- ストレージクラス
- 11 - Combustible Solids
化学と産業
薬理情報
ATC Code
R06AX29
R - Respiratory system
S - Sensory organs
QR - Respiratory system
QS - Sensory organs
Protein BindingBilastine is 84-90% bound to human plasma proteins.
PharmacodynamicsBilastine is an antiallergenic and acts to reduce allergic symptoms such as nasal congestion and urticaria.
Mechanism of Action
Bilastine is a selective histamine H1 receptor antagonist (Ki = 64nM). During allergic response mast cells undergo degranulation which releases histamine and other subastances. By binding to and preventing activation of the H1 receptor, bilastine reduces the development of allergic symptoms due to the release of histamine from mast cells.
Biological Half-LifeThe mean half life of elimination is 14.5h.
Metabolism/MetabolitesBilastine does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans.
Absorption, Distribution and Excretion
Bilastine has a Tmax of 1.13 h. The absolute bioavailability is 61%. No accumulation observed with daily dosing of 20-100 mg after 14 days. Cmax decreased by 25 % and 33% when taken with a low fat and high fat meal compared to fasted state. Administration with grapefruit juice decreased Cmax by 30%.
Bilastine is mainly excreted in the feces (66.5%) with some excreted in the urine (28.3%). Nearly all is excreted as the parent compound.
Bilastine has a total clearance is 9.20 L/h and a renal clearance of 8.7 L/h.
Metabolite PathwaysBilastine H1-Antihistamine Action
応用分野
説明Bilastine, a potent and selective histamine H1 receptor antagonist, was approved in Europe in 2010 for the treatment of allergic rhinoconjunctivitis (AR) and urticaria (hives or skin rash). The original synthesis of bilastine involves alkylation of 2-piperidinyl-1H-benzimidazole with a phenethyltosylate, the para position of which is substituted with a dimethyloxazoline moiety serving as a masked carboxylic acid group. Alkylation of the benzimidazole nitrogen with 2-chloroethyl ethyl ether followed by unmasking of the oxazoline moiety with sulfuric acid provided bilastine.In two major clinical trials, bilastine was effective at relieving allergic rhinitis as assessed by measuring the severity of nasal (obstruction, rhinorrhea, itching, sneezing) and nonnasal (ocular itching, tearing, ocular redness, itching of ears, and/or palate) symptoms.
使用Bilastine is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
関連反応
11 件
化合物ノート
読み込み中…